Effect of far-infrared radiation therapy on von Willebrand factor in patients with chronic kidney disease

October 31, 2023

Abstract

Background

Hemostatic abnormality has contributed to vascular access thrombosis in patients with chronic kidney disease (CKD). Previous studies have demonstrated that far-infrared radiation (FIR) therapy can maintain the patency and maturity of arteriovenous fistulas of patients undergoing hemodialysis (HD). However, prolonged access bleeding is observed once FIR is conducted at the end of dialysis. FIR can block the binding of platelet and von Willebrand factor (vWF), a predictor of hemostatic abnormality and vascular access thrombosis.

However, clinical studies exploring FIR and vWF are sparse.

Methods

We recruited 20 HD patients, 21 CKD patients, and 20 controls to examine the alteration of vWF and a disintegrin and metalloproteinase with thrombospondin type 1 repeats 13 (ADAMTS13) following a single 40-min session of FIR therapy. In addition, the alteration of these factors in the HD group was examined following a 40-min FIR session thrice a week for 3 months.

Results

A decreasing trend in the vWF activity-antigen ratio of participants in all groups following a single FIR session was observed. In addition, the ratio in the HD group was significantly lower following 3 months of FIR therapy. The subgroup analysis revealed a consistent trend and multiple regression analysis showed that participants not taking hydroxymethylglutaryl-coenzyme A reductase inhibitor, diabetes mellitus, and higher hemoglobin levels were the significant factors. The alteration of the vWF activity-antigen ratio correlated moderately to that of ADAMTS13 antigen and activity.

Conclusions

FIR may alter the ratio of ultra-large vWF multimers through ADAMTS13, contributing to inhibiting platelet-endothelium interactions of CKD patients.

-Front Med(Lausanne) 2023 Sep 8:10:1268212.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY

FIRAPY to Exhibit at 70th JSDT Annual Meeting in Yokohama

June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
FIRAPY was showcased at ERA 2025 in Vienna, where we reconnected with partners and met new potential

FIRAPY Showcased at ERA 2025 in Vienna

June 8, 2025
FIRAPY Medical was honored to exhibit at ERA 2025 , held at Austria Center Vienna from June 4–7, 2025 . This event marked FIRAPY’s first return to the ERA Congress since the global COVID-19 pandemic , and an important milestone in reconnecting with the European nephrology community. During the congress, our booth (X1.200) attracted considerable attention from both existing partners and new contacts. We were very encouraged by the many productive conversations and the strong interest shown by nephrology professionals across different regions. It was a great pleasure to meet some of our long-standing friends at the event, including: Stanningley Pharma (UK) — our valued distribution partner in the UK for more than 15 years Dr. Dan Heristea (France) — a nephrology expert and friend of FIRAPY Nordic MedCom (Nordic) — a familiar face from past interactions in the industry We were equally pleased to engage with potential new partners from Canada, Morocco, Panama, and the UAE . We look forward to the possibility of building new collaborations to further extend the clinical benefits of FIRAPY to more patients worldwide.  We sincerely thank everyone who visited our booth and supported us throughout the congress. We look forward to continuing these conversations and working together to advance vascular access care and patient outcomes through FIRAPY.

FIRAPY Expands Local Engagement in Thailand Through Two Key Vascular Access Events

May 26, 2025
FIRAPY was presented at two key vascular access events in Thailand, engaging with surgeons, nephrologists, and dialysis nurses on its growing clinical applications.
More Posts